Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds

Acelyrin has in-licensed izokipeb, an antibody drug developed by Affibody that could offer advantages compared to currently available monoclonal antibodies. The drug addresses the same target as blockbuster immunology drugs marketed by Novartis and Eli Lilly.